A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Biological: Placebo; Biological: MK-6194

Study type: Interventional

Funder types: Industry

Identifiers

NCT06821334

6194-014

MK-6194-014 (Other Identifier)

Details and patient eligibility

About

The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.

Enrollment: 37 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

• Is in good health
• Has body mass index (BMI) within 18.0 to 28.0 kg/m^2 (inclusive) and weight ≥50 kg

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

• History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has a history of opportunistic infection, Human immunodeficiency virus (HIV), hepatitis B, hepatitis C, tuberculosis

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Double Blind

---

37 participants in 3 patient groups

Panel A

Experimental group

Description:

Participants receive single dose subcutaneous (SC) injection of MK-6194 (Dose 1) or Placebo.

Treatment:

Biological: Placebo

Biological: MK-6194

Panel B

Experimental group

Description:

Participants receive single dose subcutaneous (SC) injection of MK-6194 (Dose 2) or Placebo.

Treatment:

Biological: Placebo

Biological: MK-6194

Panel C

Experimental group

Description:

Participants receive single dose subcutaneous (SC) injection of MK-6194 (Dose 3) or Placebo.

Treatment:

Biological: Placebo

Biological: MK-6194